-
Views
-
Cite
Cite
Yasmin Alfallouji, Ashley Spencer, Eduardo Calonje, Conal M. Perrett, Richard Watchorn, Catherine Borysiewicz, Tara Hodgkinson, Harpreet Wasan, Christopher B. Bunker, Rachel U. Sidwell, Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases, Clinical and Experimental Dermatology, Volume 47, Issue 10, 1 October 2022, Pages 1857–1858, https://doi.org/10.1111/ced.15276
- Share Icon Share
Abstract
Encorafenib is a BRAF inhibitor increasingly used as a second‐line treatment for metastatic melanoma and colorectal cancer. BRAF inhibitors have been reported to be associated with new and changing melanocytic lesions, including eruptive naevi. We describe two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF‐mutant metastatic colorectal cancer.
